AI, Hantavirus and the New Health Security

The hantavirus outbreak linked to infections aboard the MV Hondius, which arrived in the Canary Islands after several passengers were reported ill, does not necessarily point to the beginning of another Covid‑19-style global crisis. But not only because the strain currently under scrutiny — Andes hantavirus — appears significantly less transmissible than SARS‑CoV‑2. The more consequential difference is that the world now possesses technological tools that simply did not exist during the early stages of the Covid pandemic.

The World Health Organization has so far adopted a cautious but reassuring tone. Current assessments continue to indicate a low risk for the general population, even as health authorities monitor potential chains of transmission. Yet while future epidemics remain a recurring risk — in public policy as much as in economic, financial, commercial, infrastructural and even military terms — the global landscape is changing. Artificial intelligence is beginning to transform how governments, laboratories, healthcare systems and pharmaceutical companies respond to biological threats.

AI systems can already process epidemiological data in real time, identify anomalies more rapidly, model transmission scenarios, accelerate virological research and compress the timeline required to develop medical countermeasures, including vaccines and antiviral therapies. The next global health crisis — whether limited or severe — may therefore unfold in a technological environment radically different from the one that defined 2020.

This is where the hantavirus episode acquires broader strategic significance. Should a more dangerous viral threat emerge today, not all states would confront it with the same tools. Countries that have integrated artificial intelligence most deeply into their scientific, industrial, healthcare and security systems would likely be better positioned to detect, interpret and contain a fast-moving biological event.

That is the real geopolitical meaning of the hantavirus scare. The post‑Covid world is not merely better prepared than it was in 2020; it is prepared unevenly. Artificial intelligence does not make future pandemics impossible. What it can do is compress the distance between detection, analysis and response, enabling some states to coordinate more effectively and develop medical countermeasures more rapidly than others. The growing role of AI in epidemiology, virology and healthcare is therefore creating a new global hierarchy of resilience. Countries capable of combining advanced data infrastructure, computational biology, cloud capacity, biotech research and rapid decision-making may enjoy a structural advantage in the next epidemiological crisis.

The United States remains the clearest example. Its advantage stems not only from governmental preparedness, but from the density of its innovation ecosystem: Big Tech companies, research universities, pharmaceutical groups, biotech clusters, venture capital and research networks tied, in some cases, to the defence sector. China is moving in the same direction through a more state-driven model, treating AI, biotechnology and health-data infrastructure as pillars of national resilience and industrial strategy.

Yet the map now extends well beyond a simple US-China competition. Israel has built one of the world’s most sophisticated integrations of health data, cyber capabilities, AI research and emergency preparedness. Its healthcare system is comparatively digitised, its innovation ecosystem agile, and its national-security culture inclined towards rapid technological adaptation.

The Gulf, and particularly the United Arab Emirates, is moving aggressively as well. Abu Dhabi and Dubai have turned AI into a pillar of economic diversification, while simultaneously investing in digital health, cloud infrastructure and biotech partnerships. For small but capital-rich states, AI-enabled health security is increasingly becoming part of a broader strategy of national resilience.

East Asia adds another layer. Taiwan, Japan and South Korea combine advanced capabilities in semiconductors, data infrastructure, healthcare and high-tech manufacturing. Taiwan’s experience in digital public-health management, South Korea’s strengths in diagnostics and biomedical manufacturing, and Japan’s deep scientific base make them central actors in any future AI-health-security landscape. These countries may frame the issue differently, but they share a crucial asset: the ability to connect technology, industry and public systems at scale.

Europe, by contrast, risks finding itself more exposed. The European Union has played an important role in defining global standards on AI, privacy and digital governance. That regulatory instinct has undeniable value, particularly in sensitive fields such as healthcare and biology. But it also carries a strategic cost. By approaching AI primarily as a domain to regulate before deploying it at scale, Europe may have slowed the integration of AI applications into its social, industrial and healthcare systems. In a future biological crisis, the critical question may not be whether Europe possesses the world’s most sophisticated rules, but whether it has sufficient operational AI capacity embedded within its institutions.

None of this suggests that regulation is irrelevant. On the contrary, the convergence of AI and biology requires oversight. The same tools that can accelerate therapeutic discovery, model viral mutations or improve epidemiological surveillance can also generate dual-use risks. AI-assisted virology, synthetic biology and advanced genomic design raise difficult questions around biosafety, diagnostic evasion and the hostile use of emerging technologies. The answer, however, cannot be regulation without capability. The real strategic challenge is to build systems that are both powerful and governed.

That challenge is becoming more urgent because the scientific transformation is already under way. AI is making it possible to analyse biological systems at industrial scale. Advanced models can process vast genomic and proteomic datasets, helping researchers understand viral behaviour, mutation pathways and biological interactions far more rapidly than traditional methods. In virology, AI-supported tools can help study viral adaptation, interactions with host cells and the development of new therapies. In epidemiology, AI can integrate clinical, genomic, mobility and environmental data to identify anomalies before they evolve into large-scale outbreaks.

Metagenomics is especially significant. Much of the viral universe remains poorly understood. New sequencing technologies, combined with AI-driven pattern recognition, allow scientists to analyse environmental, animal and human samples on a scale that would have been impossible only a few years ago. This matters because future threats may emerge not only from known pathogens, but from a vast biological space that remains largely unexplored. The more rapidly a country can detect, classify and interpret unusual biological signals, the greater its chances of containing a threat at an early stage.

All this is changing the very logic of health security. For decades, epidemics were treated primarily as emergencies to manage once they had already erupted. The next generation of systems will be far more anticipatory: monitoring spillover risks, identifying weak signals, modelling transmission scenarios and reducing the time between identification and response. Strategically speaking, healthcare systems are beginning to evolve from treatment infrastructures into adaptive networks of health intelligence.

There is also a market dimension, though it should not be reduced to a short-term financial narrative. AI-driven health security is becoming a new industrial category, backed by governments, venture capital, cloud providers, pharmaceutical companies, diagnostics groups and biotech firms. The opportunity extends beyond drug discovery to surveillance platforms, bioinformatics infrastructure, medical-data management, intelligent hospitals and AI-enabled public-health tools. Covid demonstrated the economic cost of biological disruption. The next phase will be about building the technological infrastructure capable of reducing that disruption.

For investors, policymakers and strategic planners, the lesson is broadly the same. The value of AI in healthcare will not be measured solely by the next therapeutic or diagnostic breakthrough. It will also be measured by the capacity of societies to preserve continuity under biological stress. Countries capable of integrating AI into epidemiological surveillance, healthcare systems, virological research and emergency decision-making are likely to respond more rapidly and effectively to future biological crises.

This advantage could prove as geopolitical as it is medical. Faster and more coordinated responses reduce not only mortality, but also economic disruption, political instability and stress on supply chains. In the coming decade, AI-driven health resilience could become as strategically important as energy security or cyber capabilities.

The hantavirus episode should therefore be read primarily as a signal about the new geography of global preparedness. In the next health crisis, the decisive divide may run between states that have turned AI into an operational layer of national resilience, states that still treat it mainly as a regulatory issue, and states that still lack meaningful operational capacity. The depth of AI integration may increasingly shape not only public-health outcomes, but the ability of nations to preserve stability and respond effectively during a future pandemic phase.